VolitionRx shares rose 35% Tuesday after the company said it received $13 million in milestone payments from Heska in connection with a March 2022 licensing agreement.
Epigenetics company VolitionRx said in a securities filing that the payments arose from the successful assay transfer of its Nu.Q Vet Cancer Test onto Heska.
https://www.marketwatch.com/story/volitionrx-shares-up-35-on-13m-milestone-payments-from-heska-998612aa
No comments:
Post a Comment
Note: Only a member of this blog may post a comment.